The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02275793

Acronym

PVR

Enrollment

Registered

2014-10-27

Start date

2011-09-30

Completion date

2015-09-30

Last updated

2019-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diastolic Heart Failure, Pulmonary Hypertension

Brief summary

Peripheral blood and blood following a pulmonary wedge pressure will be obtained from patients undergoing right heart catheterizations.

Detailed description

It is well known that left sided heart disease can lead to pulmonary hypertension via a number of proposed mechanisms. The purpose in this study is to identify biomarkers in pulmonary hypertension to further understand the pathophysiology of this disease in patients with heart disease.Patients are recruited in the cardiac catheterization lab, which are undergoing right heart catheterization as per their plan of care established by their primary cardiologist. During the procedure, we will ask the performing cardiologist to obtain a blood sample of 40-50 milliliters from the catheter that they are using during the procedure. These blood samples will be sent for analysis of biomarkers. The patient will then have an echocardiogram done 1 year from their heart catheterization.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \>18 years * Ability to provide informed consent. * Presenting for cardiac catheterization for evaluation of heart disease * Ejection Fraction \> 50%

Exclusion criteria

* Unable to provide informed consent. * Unable or unwilling to comply with the protocol and follow up. * Infiltrative cardiomyopathy * Constrictive pericarditis * Severe valvular disease * Comorbid status with life expectancy \<3 years * Right ventricular dysplasia * Congenital heart disease * On immunosuppressive drugs. * Patients who has heart transplant. * Ejection Fraction \< 50% * Mean Pulmonary Artery Pressure \<25 * Wedge pressure \<15

Design outcomes

Primary

Measure	Time frame	Description
Mortality	1 year	Checking vital statistics on each patient at one year

Secondary

Measure	Time frame	Description
Morbidity	1 year	Checking vital statistics on each patient at one year

Countries

United States

Outcome results